论文部分内容阅读
本文报告了对我国首次研制成功的伤寒Ｖｉ多糖菌苗进行人体接种反应观察结果，接种对象为２０至５４岁无伤寒病史，近年无伤寒菌苗接种史的健康人，共６０名，以完全随机的方法分为两组，实验组注射３０μｇＶｉ多糖菌苗，对照组注射Ｖｉ多糖菌苗的稀释液。其结果３０名Ｖｉ多糖菌苗接种者注射后体温无中重反应发生，局部红肿仅有１例中反应。注射后对血压、心律没有影响。红细胞计数，白细胞计数均在正常范围，与接种前相比，无显著差异。标准差的波动幅度与对照接近。菌苗组注射前后白细胞分类中的中性粒细胞比例没有变化。结果证实Ｖｉ多糖菌苗的人体接种反应是轻微的，建议大面积推广应用。
This paper reports the results of human inoculation reaction of typhoid Vi polysaccharide vaccine successfully developed in China for the first time. The inoculation object is a history of non-typhoid fever from 20 to 54 years old and no history of typhoid vaccine in recent years, totally 60 Methods were divided into two groups, the experimental group injected 30μgVi polysaccharide vaccine, the control group was injected with dilution of Vi polysaccharide vaccine. The results of 30 Vi polysaccharide vaccine inoculated non-moderate body temperature after the reaction occurred, local redness in only 1 case reaction. After injection on blood pressure, heart rate has no effect. Red blood cell count, white blood cell count were in the normal range, compared with before inoculation, no significant difference. The fluctuation of standard deviation is close to that of the control. There was no change in neutrophil percentage in the leukocyte classification before and after vaccination in the vaccine group. The results confirmed that the human inoculated Vi polysaccharide vaccine reaction is minor, it is recommended to promote large-scale application.